Related Experiment Videos
Topical tacrolimus in alopecia areata
Vera H Price1, Andrea Willey, Bryan K Chen
1Department of Dermatology, University of California at San Francisco Hair Research Center, 94117, USA. pricev@derm.ucsf.edu
Journal of the American Academy of Dermatology
|January 1, 2005
Summary
Tacrolimus ointment 0.1% did not promote scalp hair regrowth in eleven patients with alopecia areata over 24 weeks. This suggests the topical formulation may not penetrate the skin effectively for this condition.
Area of Science:
- Dermatology
- Immunology
- Hair follicle biology
Background:
- Alopecia areata is an autoimmune condition causing patchy hair loss.
- Current treatments aim to modulate the immune response in the scalp.
- Topical immunosuppressants are explored for alopecia areata management.
Purpose of the Study:
- To evaluate the efficacy of tacrolimus ointment 0.1% in promoting terminal hair growth in patients with alopecia areata.
- To assess the potential of topical tacrolimus as a treatment for moderate to severe alopecia areata.
Main Methods:
- Eleven patients with alopecia areata (scalp involvement 10-75%, duration avg. 6 years) were treated.
- Tacrolimus ointment 0.1% was applied twice daily for 24 weeks.
- Outcomes were assessed by the presence or absence of terminal hair regrowth.
Main Results:
- No patient achieved terminal hair growth after 24 weeks of treatment.
- Tacrolimus ointment 0.1% demonstrated no efficacy in this patient cohort.
- The study observed a complete lack of response to the treatment.
Conclusions:
- Topical tacrolimus ointment 0.1% is ineffective for promoting hair regrowth in patients with alopecia areata.
- Treatment failure may be linked to inadequate penetration of the ointment.
- Patient selection criteria might influence treatment outcomes in alopecia areata studies.